N
Nobuhito Araki
Researcher at Osaka University
Publications - 169
Citations - 5779
Nobuhito Araki is an academic researcher from Osaka University. The author has contributed to research in topics: Sarcoma & Soft tissue sarcoma. The author has an hindex of 32, co-authored 168 publications receiving 4949 citations. Previous affiliations of Nobuhito Araki include UCLA Medical Center & Osaka Prefectural Medical Center.
Papers
More filters
Journal ArticleDOI
Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial
Winette T. A. van der Graaf,Jean-Yves Blay,Sant P. Chawla,Dong Wan Kim,B. Bui-Nguyen,Paolo G. Casali,Patrick Schöffski,Massimo Aglietta,Arthur P. Staddon,Yasuo Beppu,Axel Le Cesne,Hans Gelderblom,Ian Judson,Nobuhito Araki,M. Ouali,Sandrine Marreaud,Rachel Hodge,Mohammed R. Dewji,Corneel Coens,George D. Demetri,Christopher D.M. Fletcher,Angelo Paolo Dei Tos,Peter Hohenberger +22 more
TL;DR: This phase 3 study investigated the effect of pazopanib on progression-free survival in patients with metastatic non-adipocytic soft-tissue sarcoma after failure of standard chemotherapy.
Journal ArticleDOI
Calcium hydroxyapatite ceramic used as a delivery system for antibiotics
TL;DR: Porous blocks of calcium hydroxyapatite ceramic were evaluated as delivery systems for the sustained release of antibiotics, avoiding thermal damage to the antibiotics and a second operation for the removal of the carrier.
Journal ArticleDOI
Trabectedin monotherapy after standard chemotherapy versus best supportive care in patients with advanced, translocation-related sarcoma: a randomised, open-label, phase 2 study
Akira Kawai,Nobuhito Araki,Hideshi Sugiura,Takafumi Ueda,Tsukasa Yonemoto,Mitsuru Takahashi,Hideo Morioka,Hiroaki Hiraga,Toru Hiruma,Toshiyuki Kunisada,Akihiko Matsumine,Takanori Tanase,Tadashi Hasegawa,Shunji Takahashi +13 more
TL;DR: Trabectedin significantly reduced the risk of disease progression and death in patients with advanced translocation-related sarcoma after standard chemotherapy such as doxorubicin, and should be considered as a new therapeutic treatment option for this patient population.
Journal ArticleDOI
Synovial sarcoma is a stem cell malignancy.
Norifumi Naka,Satoshi Takenaka,Nobuhito Araki,Toshitada Miwa,Nobuyuki Hashimoto,Kiyoko Yoshioka,Susumu Joyama,Kenichiro Hamada,Yoshitane Tsukamoto,Yasuhiko Tomita,Takafumi Ueda,Hideki Yoshikawa,Kazuyuki Itoh +12 more
TL;DR: Data suggest that a human multipotent mesenchymal stem cell can serve as a cell of origin for SS and SS is a stem cell malignancy resulting from dysregulation of self‐renewal and differentiation capacities driven by SS18‐SSX fusion protein.
Journal Article
Genome-wide analysis of gene expression in synovial sarcomas using a cDNA microarray.
Satoshi Nagayama,Toyomasa Katagiri,Tatsuhiko Tsunoda,Taisuke Hosaka,Yasuaki Nakashima,Nobuhito Araki,Katsuyuki Kusuzaki,Tomitaka Nakayama,Tadao Tsuboyama,Takashi Nakamura,Masayuki Imamura,Yusuke Nakamura,Junya Toguchida +12 more
TL;DR: Examination of genome-wide gene expression profiles of synovial sarcoma cases by cDNA microarray identified a set of genes that divided SS cases into two putative subclasses, a feature that may shed light on novel biological aspects of SS in addition to those having to do with epithelial differentiation.